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from the database sourced from the UK drug tariff, BNF and
MIMS (with appropriate assumptions where quantities were
unclear). RESULTS: In total, 3581 patients met the inclusion
criteria. The average dose of insulin in T2D patients within the
study was 36IU/day at 12 months. The average yearly cost was
384 for insulin alone and ancillary item cost reached 223
increasing total annual cost of insulin and equipment to 607.
CONCLUSION: Although clinically appropriate for some T2D
patients, insulin is expensive, particularly when ancillaries are
considered.This database study was a straightforward way of
identifying and analysing not only drug costs but ‘hidden’ costs
of insulin ancillaries.This analysis only takes account of insulin
and ancillary costs and does not account for visits to health care
professionals. Initiation of insulin is often accompanied by extra
visits to health care professionals, which would further increase
costs.
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OBJECTIVES: The primary objective of the INSTIGATE study is
to assess the direct costs of care for type 2 diabetes in the 6
months before and after insulin initiation. This abstract presents
data for patients enrolled in Germany and UK. METHODS:
INSTIGATE is an ongoing prospective European observational
study investigating patients with type 2 diabetes who have initi-
ated insulin during usual care. The direct costs of diabetes care
over the 6 months prior to and after insulin initiation were
calculated by collecting data on individual resource use and
assigning local unit costs. Data collected included; number of
consultations with health care professionals, details of oral anti-
diabetic medications and insulins, hospitalisations for diabetes
care or complications, and frequency of blood glucose monitor-
ing. RESULTS: Five hundred and nine patients were enrolled in
Germany and UK, and 6 month follow-up data was collected
from 457 patients. In Germany the median costs per patient for
diabetes care in the 6 months prior to and after insulin initiation
were 406€ and 893€ respectively. In the UK the median costs per
patient for diabetes care in the 6 months prior to and after insulin
initiation were 596€ and 707€ respectively (2006 costs). CON-
CLUSION: For German and UK patients included in this study
the median cost of care for diabetes in the 6 months following
insulin initiation is higher than in the 6 months prior to insulin
initiation. Differences in types of resource use pre and post
insulin initiation have been observed and further analysis is
underway to investigate how these differences, and the cost of
insulin, are impacting costs of care. Outcomes following insulin
initiation will also be investigated.
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OBJECTIVES: In Spain there are several pharmaceutical prod-
ucts for the treatment of type 2 diabetes mellitus (DM2), with
different proﬁles which implies alternative patterns of adminis-
tration. A comparative study comparing annual costs linked to
the treatment with Glargine insulin (GI) and Detemir insulin (DI)
has been performed with the Spanish National Health System
perspective. METHODS: Clinical data related with each treat-
ment derives, mainly, from a study performed by Rosenstock
et.al (2006): a 52-week open-label, parallel, multinational trial,
which compares efﬁcacy and safety of GI and DI. This trial has
shown that patients treated with GI required less dairy dose of
insulin and suffer from less severe hypoglycaemia than those
patients treated with DI. Data about other use of related medical
resources (consumption of needles and blood glucose tests,
and management of major hypoglycaemic episodes) has been
obtained from Spanish published literature. Costs calculations
refer to year 2007 and have been derived from Spanish databases
and published tariffs. RESULTS: Patients treated with ID require
65% more dose than those treated with GI, and suffer more
major hypoglycaemic events. In patients with DM2 management
with GI has lower total costs than DI, which allows savings up to
534.96€ per patient-year. Savings are related with costs of total
insulin, needles and blood glucose tests and also medical man-
agement required in case of major hypoglycaemic events. CON-
CLUSION: For patients with DM2 treatment with GI is an
efﬁcacious and safe therapeutic option compared with DI,
because GI is associated with lower annual total costs, and
allows saving up to 534.96€ per patient-year i.e. a 34% saving
per patient-year.
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OBJECTIVES: Pregnant women with diabetes report high rates
of neonatal mortality and morbidity. The costs of resulting inter-
ventions are potentially substantial. This study investigated
health outcomes and inpatient costs in pregnant women with
type 1 diabetes. METHODS: This analysis utilised a cohort of
302 pregnant women with type 1 diabetes, enrolled before 10
weeks gestation, with HbA1C  8% at conﬁrmation of preg-
nancy and for whom birth outcome was known. Subjects were
participating in a randomised study of basal-bolus insulin regi-
mens, with doses titrated in line with the American Diabetes
Association (ADA) guidelines. Outcomes recorded included
major maternal hypoglycaemia, neonatal hypoglycaemia, obstet-
ric complications, congenital malformations, foetal loss, birth
before 37 weeks gestation, birth weight >4000 g, and other
adverse events if life threatening or requiring hospitalisation.
Resulting inpatient costs were estimated from the perspective of
the UK National Health Service. RESULTS: The percentage of
subjects reporting major maternal hypoglycaemia was 29%,
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neonatal hypoglycaemia 53%, foetal loss 11%, preterm deliv-
ery 22%, obstetric complications 33%, congenital malforma-
tions 5%, birth weight >4000 g 20%, and other adverse events
12%. The mean inpatient cost per subject was 4589
(SD  3961). The main costs were admission for pre-term
infants (3089, SD  3508), adverse events and obstetric com-
plications (532, SD  839), and normal delivery costs (968,
SD  328). The mean cost was around four times the average
cost of delivery in a UK hospital (1078). In England and
Wales around 5250 women with type 1 diabetes give birth
every year. The excess cost of these births to the NHS is around
18.4 million per annum. CONCLUSION: Inpatient costs
are high in pregnant women with type 1 diabetes. Successful
intervention in this group could improve health outcomes and
substantially reduce cost.
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OBJECTIVES: Hemoglobin A1c (HbA1c), a clinical measure of
ambient blood glucose concentrations over the previous 3
month time period, is recognized as a surrogate measure for
the risk of complications among patients with diabetes. The
purpose of this research is to quantify the impact of changes
in glycemic control on diabetes-related medical costs.
METHODS: Data from the i3 LabRx Database were used for
this study. Individuals were included in the analysis if they had
two diagnoses of type 2 diabetes (ﬁrst diagnosis identiﬁed as
the index date), had one valid HbA1c test result recorded in the
six months prior to the index date and had at least one valid
HbA1c test result recorded in the twelve months post index
date (N = 2,239). Multivariate regressions were used to
examine the relationship between the change in HbA1c from
the post-period to the pre-period on diabetes related costs,
while controlling for patient characteristics, general health
status, comorbidities, timing between the post and pre-period
HbA1c tests, and initial value of HbA1c. RESULTS: Thirty
percent of the individuals in this sample were found to have an
initial HbA1c value greater than 7. Results from the multivari-
ate analyses indicate that after controlling for other factors
which may impact diabetes-related costs, a one point reduction
in HbA1c value was associated with a $433 reduction in total
one-year diabetes-related medical costs (p = 0.0033). In addi-
tion, a one point reduction in HbA1c value was also associated
with a signiﬁcant reduction in diabetes-related outpatient
costs (-$127, p = 0.0268) as well as a signiﬁcant reduction in
diabetes-related outpatient prescription drug costs (-$293,
p < 0.0001). CONCLUSION: Evidence from this analysis indi-
cates that the direct medical costs of treating type 2 diabetes
are signiﬁcantly reduced as HbA1c values are reduced. These
results highlight that there are savings associated with a one
point reduction in patients’ glycemic control.
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OBJECTIVES: The aim of this study was to estimate the cost-
utility of type 1 diabetes patients treated with detemir based
basal-bolus therapy versus neutral protamine Hagedorn (NPH)
insulin based basal-bolus therapy in France using results
obtained from a meta-analyses of three clinical trials. The meta-
analyses demonstrated a short-term improvement for detemir
over NPH in HbA1c (0.13% points lower), a decrease in
hypoglycemic events (by 4%) and lower body mass index (BMI)
(0.21 kg.m-2). METHODS: A published, validated, peer-
reviewed computer simulation model of diabetes (the CORE
Diabetes Model) was used to project short-term results obtained
from the ﬁxed-effects meta-analysis to long-term clinical and cost
outcomes (including life quality adjusted life expectancy, inci-
dence of complications, and direct medical costs), when basal
detemir or NPH is used in combination with either insulin aspart
or human soluble insulin. Probabilities of complications were
derived from landmark clinical and epidemiological studies.
The costs of treating complications and appropriate baseline
comorbidities were retrieved from published sources and France
speciﬁc mortality rates applied. Total direct medical costs
(complications + treatment costs) were projected over patient
lifetimes, and future costs and clinical beneﬁts discounted at 3%
per annum. RESULTS: Therapeutic beneﬁts of superior glycemic
control, lower hypoglycemic event rates and reduced BMI asso-
ciated with detemir based basal-bolus therapy led an increase in
quality-adjusted life expectancy of 0.190 years (7.38  0.09
versus 7.18  0.09) versus NPH. Increased total lifetime costs/
patient of €2,370 (€75,477  2109 versus €73,106  2165)
with detemir resulted in an incremental cost-effectiveness ratio of
€12,477 per quality-adjusted life year (QALYs) gained. CON-
CLUSION: Therapeutic improvements demonstrated in the
meta-analyses of detemir can be reasonably expected to lead to
decreases in long-term complications, improvements in quality-
adjusted life expectancy and a cost-effectiveness ratio which falls
well below a range considered to represent good value for money
(<€50,000/QALY gained).
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OBJECTIVES: To evaluate long-term economic outcomes in the
Swedish setting for type 2 diabetes patients treated with either
mealtime insulin aspart (IAsp, NovoRapid) or human insulin
(HI) as part of basal-bolus therapy, based on ﬁndings from the
European PREDICTIVE study (Predictable Results and Experi-
ence in Diabetes through Intensiﬁcation and Control to Target:
an International Variability Evaluation). METHODS: The
CORE Diabetes Model, a published and validated computer
simulation model was used to project long-term outcomes and
account lifetime costs for patients receiving either IAsp or HI.
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